No CrossRef data available.
Article contents
Aripirazole-Long Acting Injectable in Pregnant Women with Schizophrenia: A Case Series
Published online by Cambridge University Press: 01 September 2022
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
Long-acting injectable antipsychotics (LAIs) have emerged as a new therapeutic option to treat patients suffering a psychotic disorder. To date, there is a lack of studies regarding safety and clinical use pattern of LAIs in pregnant women.
Objectives
Provide evidence and real world clinical data of pregnant women with schizophrenia who have been treated with long-acting aripiprazole monohydrate (aripiprazole once monthly [AOM] condition) during their pregnancy.
Methods
Descriptive real-world clinical experiences of pregnant women in treatment with AOM. The information was obtained by reviewing electronic medical records and by direct clinical observation management.
Results
The first six case-series describing the pregnancy course of women with schizophrenia treated with AOM. All of them remained psychopathologically stable through pregnancy, and their infants became healthy with normal developmental milestones (Table 1).
Table 1.
Clinical characteristics of six case-reports.
| Mothers | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| Maternal/Pregnancy outcomes | ||||||
| Age(years) | 35 | 29 | 35 | 31 | 38 | 30 |
| Diagnosis | Schizophrenia | Schizophrenia | Schizophrenia | Schizophrenia | Schizophrenia | Schizophrenia |
| AOM(mg/days) | 400-300 | 400-300 | 400-300 | 160 | 300 | 400 |
| Type of delivery | Eutocic. | Eutocic, preterm | Eutocic | Eutocic | Eutocic | Eutocic |
| Neonatal outcomes | ||||||
| Weight(grams) | 3300 | 1800 | 3140 | 3102 | 2940 | 3400 |
| Gender | Female | Female | Male | Male | Male | Male |
| Developmental Abnormalities(years) | No(3) | No(2) | No( 0.17) | No(2) | No(2) | No(1.5) |
Conclusions
The favorable results in this case-series suggest that despite the lack of evidence on reproductive safety and treatment with AOM during pregnancy, this therapeutic option should be considered in pregnant women with schizophrenia. However, further research on the use of long-acting antipsychotics in pregnant women is needed.
Disclosure
No significant relationships.
Keywords
- Type
- Abstract
- Information
- European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S129 - S130
- Creative Commons
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.- Copyright
- © The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
You have
Access
Open access
Comments
No Comments have been published for this article.